{"id":1121909,"date":"2026-07-31T10:12:18","date_gmt":"2026-07-31T10:12:18","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/1121909\/"},"modified":"2026-07-31T10:12:18","modified_gmt":"2026-07-31T10:12:18","slug":"bristol-myers-squibb-bmy-earnings-beat-and-higher-outlook-put-valuation-back-in-focus","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/1121909\/","title":{"rendered":"Bristol Myers Squibb (BMY) Earnings Beat And Higher Outlook Put Valuation Back In Focus"},"content":{"rendered":"\n

Track your investments for FREE<\/a> with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. <\/p>\n

Bristol-Myers Squibb (BMY) reported second quarter 2026 results that exceeded Wall Street expectations, with revenue and earnings per share ahead of forecasts and management raising full year guidance for both measures. <\/p>\n

See our latest analysis for Bristol-Myers Squibb.<\/a> <\/p>\n

The strong Q2 surprise has come on top of an already solid run for Bristol-Myers Squibb, with a 1-month share price return of 12.57% and a year to date share price return of 21.32%. Over a longer horizon, total shareholder return of 56.95% over the past year and 21.99% over three years points to momentum that investors are watching closely. <\/p>\n

If this earnings beat has you thinking more broadly about healthcare opportunities, it could be a useful moment to scan other potential ideas using our healthcare focused AI stock screener, starting with 41 healthcare AI stocks<\/a>. <\/p>\n

Bulls point to Bristol-Myers Squibb’s Q2 beat and higher guidance as evidence the recent rally still has room. Bears see a mature pharma group with slowing annual revenue and profit growth. Which side does current valuation support? <\/p>\n

Most Popular Narrative: 3% Overvalued <\/p>\n

Bristol-Myers Squibb closed at $64.86, which sits slightly above the most widely followed fair value estimate of $62.96 that anchors the current narrative. <\/p>\n

\n

Robust late-stage pipeline and ongoing life-cycle management for major brands plus strategic partnerships (BioNTech, Philochem, Bain) expand the breadth of future regulatory approvals and label expansions, opening additional indications and helping to offset upcoming patent expiries, which underpins top-line and earnings growth. <\/p>\n<\/blockquote>\n

Read the complete narrative. Read the complete narrative.<\/a> <\/p>\n

Curious how this slight premium is justified. The narrative leans on shrinking headline revenue, rising margins, and a richer future earnings multiple to support that fair value. <\/p>\n

Result: Fair Value of $62.96 (OVERVALUED)<\/strong> <\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a> <\/p>\n

However, there are clear pressure points that could upset this Bristol-Myers Squibb story, including upcoming patent cliffs for key drugs and tougher global drug pricing that could squeeze margins. <\/p>\n

Find out about the key risks to this Bristol-Myers Squibb narrative.<\/a> <\/p>\n

Another View on Bristol-Myers Squibb Valuation <\/p>\n

The Simply Wall St DCF model presents a very different picture for Bristol-Myers Squibb. On this view, the stock at $64.86 trades well below an estimated future cash flow value of $122.58. This frames BMY as materially undervalued compared with the earlier 3% overvalued narrative. Which story do you think fits your assumptions? <\/p>\n

For readers who want to see how this cash flow view is built step by step, Look into how the SWS DCF model arrives at its fair value.<\/a> <\/p>\n

\"BMY<\/a> BMY Discounted Cash Flow as at Jul 2026 Next Steps <\/p>\n

With Bristol-Myers Squibb drawing mixed views from bulls and bears, now is a good time to move quickly and study the full picture for yourself. To weigh the balance between potential upside and the issues investors are watching, start by reviewing the 3 key rewards and 3 important warning signs<\/a>. <\/p>\n

Looking For More Investment Ideas Beyond Bristol-Myers Squibb? <\/p>\n

If you are weighing your next move after Bristol-Myers Squibb, do not stop at one stock. Broader idea hunting now could shape the strength of your portfolio. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.<\/strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include BMY<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? <\/strong>Get in touch<\/strong><\/a> with us directly.<\/strong> Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…\n","protected":false},"author":2,"featured_media":1077481,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[8818],"tags":[381,23890,748,18336,393,24090,4884,16,15],"class_list":["post-1121909","post","type-post","status-publish","format-standard","has-post-thumbnail","category-bristol","tag-bristol","tag-bristol-myers-squibb","tag-britain","tag-earnings-per-share","tag-england","tag-fair-value","tag-great-britain","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/117014059412393132","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1121909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1121909"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1121909\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1077481"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1121909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1121909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1121909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}